Streetbeat News

Products Services

ORIC

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting. The study included a heavily pretreated patient population and ORIC-533 was well tolerated with no dose limiting toxicities. Preliminary evidence of enhanced CD8+ T-cell activation was seen at the highest dose levels tested and early evidence of single agent clinical activity was observed.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:12 pm

CNTA

Centessa Pharmaceuticals will present additional 52-weeks of continuous treatment data from the third year of an ongoing Phase 2a study of SerpinPC for the treatment of Hemophilia at the ASH Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:12 pm

LXRX

Lexicon Pharmaceuticals (NASDAQ:LXRX) announced that five data presentations related to INPEFA® (sotagliflozin) will be delivered during the American Heart Association Scientific Sessions 2023. The presentations will highlight the early clinical benefit of INPEFA for heart failure and atherosclerotic events, and the cost-effectiveness metrics associated with the use of INPEFA. The FDA recently approved INPEFA for the treatment of heart failure.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:12 pm

IRON

Disc Medicine, Inc. (NASDAQ:IRON) has announced the completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP). The company will present preliminary data from these studies and from phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia at the 65th American Society of Hematology (ASH) Annual Meeting. The company will also host a conference call on December 11th to discuss these updates.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:11 pm

ALPN

Alpine Immune Sciences has presented initial clinical data on Povetacicept in autoimmune glomerulonephritis at the American Society of Nephrology Kidney Week 2023. The low-dose Povetacicept was well tolerated and reduced UPCR by over 50% in IgA nephropathy. The company is now planning to begin a pivotal phase 3 IgAN study in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:11 pm

APTO

Aptose Biosciences Inc. (NASDAQ:APTO) announced that clinical data for its drug tuspetinib has been selected for oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting in December 2023. The data will be presented by Naval Daver from the University of Texas MD Anderson Cancer Center and will include updates from Aptose's ongoing APTIVATE trial of tuspetinib in patients with acute myeloid leukemia.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:11 pm

KYMR

Kymera Therapeutics (NASDAQ:KYMR) announced new clinical data from the Phase 1 trial of STAT3 degrader KT-333, highlighting safety, pharmacokinetics, pharmacodynamics, and clinical responses. The data will be presented at the ASH 65th Annual Meeting and Exposition in December 2023. The abstract reported Phase 1 data from 21 patients, with one partial response reported after two cycles in a CTCL patient and stable disease reported after two cycles in three solid tumor patients. No dose limiting toxicities or serious adverse events were reported.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:10 pm

SCLX

Scilex Holding Company (NASDAQ:SCLX) has announced a positive Type C meeting with the U.S. Food and Drug Administration (FDA), reaching an agreement on the path forward to advance the clinical development of SP-102 and on the requirements to file a New Drug Application (NDA). Scilex plans to commence an open-label multi-center safety and efficacy trial in the first half of 2024, with completion of enrollment projected to occur in 2025. If approved, SP-102 would be the first corticosteroid with an indication for epidural administration in the U.S.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:10 pm

SCLX

Scilex Holding Company (NASDAQ:SCLX) has announced new data from skin penetration studies supporting SP-103 5.4%, a triple strength formulation of ZTlido, in the treatment of musculoskeletal pain disorders. The studies showed a higher diffusive transport of lidocaine compared to diclofenac, with SP-103 resulting in a significantly higher lidocaine concentration in muscle tissue than commercially available ZTlido. The company believes these results indicate that SP-103 is highly effective in delivering lidocaine into muscle tissue in areas of localized pain.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:09 pm

SDGR

Schrödinger (NASDAQ:SDGR) announced that new data on its investigational drugs SGR-1505 and SGR-2921 will be presented at the American Society of Hematology (ASH) 65th Annual Meeting. The data supports the continued development of SGR-1505 as a potential therapy for patients with advanced B-cell malignancies. SGR-2921 has shown strong anti-leukemic activity in preclinical models of acute myeloid leukemia (AML). The company will review these data as part of its Pipeline Day on December 14, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:08 pm